

# DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

October 2012

Vol. 40, No. 10

## CONTENTS

### COMMENTARY

- Theoretical Predictions of Flow Effects on Intestinal and Systemic Availability in Physiologically Based Pharmacokinetic Intestine Models: The Traditional Model, Segregated Flow Model, and  $Q_{Gut}$  Model. *K. Sandy Pang and Edwin C. Y. Chow* . . . . . **1869**

### SHORT COMMUNICATION

- Selective Expression of CYP2A13 in Human Pancreatic  $\alpha$ -Islet Cells. *Yu Guo, Liang-Ru Zhu, Gang Lu, Hui Wang, and Jun-Yan Hong* . . . . . **1878**

### ARTICLES

- Breast Cancer Resistance Protein (ABCG2) Determines Distribution of Genistein Phase II Metabolites: Re-evaluation of the Roles of ABCG2 in the Disposition of Genistein. *Zhen Yang, Wei Zhu, Song Gao, Taijun Yin, Wen Jiang, and Ming Hu* . . . . . **1883**

- Selective Modulation of Hepatic Cytochrome P450 and Flavin Monooxygenase 3 Expression during *Citrobacter rodentium* Infection in Severe Combined Immune-Deficient Mice. *Beatrice A. Nyagode, William J. Watkins, Ryan D. Kinloch, and Edward T. Morgan* . . . . . **1894**

- Key Role of Nuclear Factor- $\kappa$ B in the Cellular Pharmacokinetics of Adriamycin in MCF-7/Adr Cells: The Potential Mechanism for Synergy with 20(S)-Ginsenoside Rh2. *Jingwei Zhang, Meng Lu, Fang Zhou, Haopeng Sun, Gang Hao, Xiaolan Wu, and Guangji Wang* . . . . . **1900**

- Microdialysis Evaluation of Clozapine and *N*-Desmethylclozapine Pharmacokinetics in Rat Brain. *Thomas I. F. H. Cremers, Gunnar Flik, Corry Hofland, and Robert E. Stratford, Jr.* . . . . . **1909**

- Comparison of Metabolism of Sesamin and Episesamin by Drug-Metabolizing Enzymes in Human Liver. *Kaori Yasuda, Shinichi Ikushiro, Shuto Wakayama, Toshimasa Itoh, Keiko Yamamoto, Masaki Kamakura, Eiji Munetsuna, Miho Ohta, and Toshiyuki Sakaki* . . . . . **1917**

- In Vitro Characterization of the Drug-Drug Interaction Potential of Catabolites of Antibody-Maytansinoid Conjugates. *John A. Davis, Dan A. Rock, Larry C. Wienkers, and Josh T. Pearson* . . . . . **1927**

- Human UDP-Glucuronosyltransferase Expression in Insect Cells: Ratio of Active to Inactive Recombinant Proteins and the Effects of a C-Terminal His-Tag on Glucuronidation Kinetics. *Hongbo Zhang, Anne-Sisko Patana, Peter I. Mackenzie, Shinichi Ikushiro, Adrian Goldman, and Moshe Finel* . . . . . **1935**

- The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole. *Mosun A. Ayan-Oshodi, Brian A. Willis, William F. Annes, Stephen L. Lowe, Stuart Friedrich, Amparo de la Peña, Wei Zhang, Thomas Brown, Stephen D. Wise, and Stephen D. Hall* . . . . . **1945**

- Xenobiotic Metabolism and Disposition in Human Lung Cell Models: Comparison with In Vivo Expression Profiles. *Elisabeth Courcot, Julie Leclerc, Jean-Jacques Lafitte, Eric Mensier, Sophie Jaillard, Philippe Gosset, Pirouz Shirali, Nicolas Pottier, Franck Broly, and Jean-Marc Lo-Guidice* . . . . . **1953**

- High-Resolution Mass Spectrometry Elucidates Metabonate (False Metabolite) Formation from Alkylamine Drugs during In Vitro Metabolite Profiling. *Joanna E. Barbara, Faraz Kazmi, Seema Muranjan, Paul C. Toren, and Andrew Parkinson* . . . . . **1966**

- CYP2E1 Metabolism of Styrene Involves Allostery. *Jessica H. Hartman, Gunnar Boysen, and Grover P. Miller* . . . . . **1976**

- Human Liver Methionine Cycle: *MAT1A* and *GNMT* Gene Resequencing, Functional Genomics, and Hepatic Genotype-Phenotype Correlation. *Yuan Ji, Kendra K. S. Nordgren, Yubo Chai, Scott J. Hebring, Gregory D. Jenkins, Ryan P. Abo, Yi Peng, Linda L. Pellemounter, Irene Moon, Bruce W. Eckloff, Xiaoshan Chai, Jianping Zhang, Brooke L. Fridley, Vivien C. Yee, Eric D. Wieben, and Richard M. Weinshilboum* . . . . . **1984**

Continued on next page

- In Vivo-Formed versus Preformed Metabolite Kinetics of *trans*-Resveratrol-3-sulfate and *trans*-Resveratrol-3-glucuronide. *Satish Sharan, Orito F. Iwuchukwu, Daniel J. Canney, Cheryl L. Zimmerman, and Swati Nagar* . . . . . **1993**
- ☐ Acetylenic Linkers in Lead Compounds: A Study of the Stability of the Propargyl-Linked Antifolates. *Wangda Zhou, Kishore Viswanathan, Dennis Hill, Amy C. Anderson, and Dennis L. Wright* . . . . . **2002**
- Mechanistic Studies on the Absorption and Disposition of Scutellarin in Humans: Selective OATP2B1-Mediated Hepatic Uptake Is a Likely Key Determinant for Its Unique Pharmacokinetic Characteristics. *Chunying Gao, Hongjian Zhang, Zitao Guo, Tiangeng You, Xiaoyan Chen, and Dafang Zhong* . . . . . **2009**
- Glycemic Control and Chronic Dosing of Rhesus Monkeys with a Fusion Protein of Iduronidase and a Monoclonal Antibody Against the Human Insulin Receptor. *Ruben J. Boado, Eric Ka-Wai Hui, Jeff Zhiqiang Lu, and William M. Pardridge* . . . . . **2021**
- Absolute Oral Bioavailability and Metabolic Turnover of  $\beta$ -Sitosterol in Healthy Subjects. *Guus Duchateau, Brett Cochrane, Sam Windebank, Justyna Herudzinska, Davindera Sanghera, Angela Burian, Markus Müller, Markus Zeitlinger, and Graham Lappin* . . . . . **2026**
- Regulation of Pregnane X Receptor (PXR) Function and *UGT1A1* Gene Expression by Posttranslational Modification of PXR Protein. *Junko Sugatani, Takahiro Uchida, Masatoshi Kurosawa, Masahiko Yamaguchi, Yasuhiro Yamazaki, Akira Ikari, and Masao Miwa* . . . . . **2031**
- ☐ In Vitro Studies on the Oxidative Metabolism of 20(*S*)-Ginsenoside Rh2 in Human, Monkey, Dog, Rat, and Mouse Liver Microsomes, and Human Liver S9. *Liang Li, Xiaoyan Chen, Jialan Zhou, and Dafang Zhong* . . . . . **2041**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

*About the cover:* Propargyl-linked lead compounds. Top, propargyl-linked antifolates and their IC<sub>50</sub> and MIC values against *S. aureus* DHFR and methicillin-resistant *S. aureus*. Bottom, compound 1 bound to *C. glabrata* DHFR. See the article by Zhou et al. on page 2002 of this issue.